Metraipolis › archive › dc_69b80d96db36
Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial — Europe PMC PMID:41582387
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41582387
- DOI
- 10.2174/0118715303398749251027044323
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-07T05:40:15.021Z
- SHA-256 of the archived text
75596b927e3a46ab7f0211abaf7b3626ecd6583c777092d27c83f6492f39d956- Stable URL of this page
https://metraipolis.com/documento/dc_69b80d96db36
How to cite
Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial — Europe PMC PMID:41582387 — Europe PMC (en), https://europepmc.org/article/MED/41582387 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_69b80d96db36 (Metraipolis archive dc_69b80d96db36, sha256 75596b927e3a46ab7f0211abaf7b3626ecd6583c777092d27c83f6492f39d956)
BibTeX
@misc{dc69b80d96db36,
title = {Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled Trial — Europe PMC PMID:41582387},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41582387},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_69b80d96db36; sha256 75596b927e3a46ab7f0211abaf7b3626ecd6583c777092d27c83f6492f39d956},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41582387. Agents can read the archived copy with the MCP tool read_document.